Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer

1984 ◽  
Vol 4 (4) ◽  
pp. 283-288 ◽  
Author(s):  
Grace Wang ◽  
Charles L Vogel ◽  
Susan G Hilsenbeck ◽  
Walter Voigt ◽  
Sharon Thomsen
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Estrogen Receptors ◽  
Metastatic Breast ◽  
Prediction Of Response ◽  
Hormonal Manipulation

The variability of estrogen receptors in metastatic breast cancer

1979 ◽  
Vol 137 (2) ◽  
pp. 260-262 ◽  
Author(s):  
Michael J. Brennan ◽  
William L. Donegan ◽  
Douglas E. Appleby
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Estrogen Receptors ◽  
Metastatic Breast

Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer

2002 ◽  
Vol 20 (9) ◽  
pp. 2319-2326 ◽  
Author(s):  
Catherine Van Poznak ◽  
Lee Tan ◽  
Katherine S. Panageas ◽  
Crispinita D. Arroyo ◽  
Clifford Hudis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Metastatic Breast Cancer ◽  
Estrogen Receptors ◽  
Clinical Response ◽  
Performance Status ◽  
Single Agent ◽  
Progesterone Receptors ◽  
Metastatic Breast ◽  
Taxane Chemotherapy

PURPOSE: The taxanes affect tubulin polymerization and interfere with mitotic transition. A checkpoint blockade at the G1-S boundary would be expected to promote taxane-induced apoptotic cell death through a mechanism that may involve p27. Other proposed determinants of clinical taxane sensitivity/resistance include p53, members of the epidermal growth factor receptor (EGFR) superfamily (eg, HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study. PATIENTS AND METHODS: We performed immunohistochemistry (IHC) for estrogen receptors, progesterone receptors, HER2, EGFR, p53, and p27 on 144 breast tumor specimens from patients treated for metastatic breast cancer on a series of clinical trials of single-agent taxane chemotherapy for correlation with clinical response (complete or partial response). Patient characteristics that could influence response (ie, performance status, extent of disease, and prior therapy) were also examined. RESULTS: In univariate analysis, Karnofsky performance status ≥ 90% and no prior history of anthracycline therapy correlated with a good clinical response to single-agent taxane (P = .003 and P = .041, respectively). None of the IHC variables tested were predictive of clinical response to taxane therapy, although p27 negativity showed a trend toward significance (P = .075). Concordance between the polyclonal antibody with HercepTest (DAKO, Carpinteria, CA) and the monoclonal antibody CB-11 (BioGenex, San Ramon, CA) was noted (kappa = 0.943); however, neither univariate nor multivariate analysis demonstrated an association between HER2 status and response to taxane chemotherapy. CONCLUSION: The IHC biomarkers studied were not predictive of response to single-agent taxane chemotherapy in patients with metastatic breast cancer. Identification of molecular correlates of taxane response remains an important goal.

Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE.

1997 ◽  
Vol 15 (7) ◽  
pp. 2536-2545 ◽  
Author(s):  
L J Rijks ◽  
P J Bakker ◽  
G van Tienhoven ◽  
L A Noorduyn ◽  
G J Boer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Estrogen Receptors ◽  
Single Photon ◽  
Photon Emission ◽  
Metastatic Breast ◽  
Emission Computed Tomography ◽  
Breast Cancer Patients ◽  
Planar Scintigraphy ◽  
Iodine 123

PURPOSE To evaluate the feasibility of noninvasive imaging of estrogen receptors (ERs) in primary and metastatic breast cancer with the iodine-123-labeled ER-specific ligand cis-11beta-methoxy-17alpha-iodovinylestradiol-17beta (Z-[123I]MIVE) using conventional nuclear medicine techniques. PATIENTS AND METHODS Z-[123I]MIVE planar scintigraphy and single-photon emission computed tomography (SPECT) were performed in 12 patients with proven primary breast cancer and 13 patients with proven or from other imaging modalities evident bone, liver, lung, pleura and/or lymph node metastases. The results were compared with those of ER immunohistochemistry (IHC). Blocking studies with the antiestrogen tamoxifen were performed to test whether Z-[123I]MIVE tumor uptake was ER-mediated. RESULTS Planar imaging showed uptake in 11 of 12 primary carcinomas. ER IHC performed for nine of these was positive. For the planar scintigraphy-negative patient, SPECT was faintly positive, but ER IHC negative (agreement, 90%). In nine of 13 metastatic patients, planar scintigraphy was positive. The agreement between the results of ER IHC on the original primary tumor and of Z-[123I]MIVE scintigraphy was 82%. Specificity of tumor Z-[123I]MIVE uptake was established by complete blockade of uptake by tamoxifen, except in two patients who showed progressive disease. Z-[123I]MIVE scintigraphy also enabled discriminating metastases from confounding nonmalignant abnormalities of the bone scan. CONCLUSION Z-[123I]MIVE scintigraphy shows high sensitivity and specificity for the detection of ER-positive breast cancer. This may have impact on diagnostic possibilities and therapeutic management. Since ER imaging shows the functional status, addressing known intratumoral and intertumoral ER heterogeneity, it may improve the characterization of disease and the selection of patients who may benefit from hormonal therapy.

Prediction of Response to Hormonal Treatment in Metastatic Breast Cancer

Oncology ◽  
2002 ◽  
Vol 63 (4) ◽  
pp. 309-316 ◽  
Author(s):  
P. Schmid ◽  
M.B. Wischnewsky ◽  
O. Sezer ◽  
R. Böhm ◽  
K. Possinger
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Hormonal Treatment ◽  
Prediction Of Response
Sign in / Sign up

Export Citation Format

Share Document